Targeting cytokine pathways: the role of biologics in autoinflammatory disorders
IL-1 inhibition has transformed the management of inflammasome-mediated diseases, enabling glucocorticoid-free remission and reducing amyloidosis risk. TNF inhibitors remain standard for vasculopathic disorders such as DADA2, while IL-6 blockade and JAK inhibitors are options in selected refractory cases. The recognition of novel syndromes, including HA20, OTULIN deficiency, and PRAAS, has broadened the therapeutic landscape, and next-generation biologics may further enable personalized treatment.
Authors
- Tomohiro Koga (ORCID: https://orcid.org/0000-0003-2077-4428)
Institutions
- Nagasaki University (JP)
Publication Details
- Journal
- Expert Review of Clinical Immunology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/1744666x.2026.2625277
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00